Hillian, Kenneth
This speaker appears at this event:

This speaker’s events are being finalized

Kenneth Hillan, MD

  • Head of Therapeutics, 23andMe

Kenneth joined 23andMe in 2019 as Head of Therapeutics. He leads a dedicated discovery research and therapeutic development team that uses human genetic data to identify and pursue novel therapies for common and rare diseases.
Kenneth held leadership roles at Genentech from 1994 to 2011. He led the medical and scientific strategies for its Immunology, Tissue Growth and Repair drug portfolio. He served in a number of key leadership positions in research and development, including Senior Vice President Clinical Development, Inflammation, Vice President Immunology, Tissue Growth and Repair (ITGR), Vice President Development Sciences and Vice President Research Operations and Pathology. He also served as Senior Vice President and Head of Clinical Development and Product Development Strategy in Asia-Pacific for Roche in Shanghai, China.
Kenneth has served on the board of directors of Achaogen, Inc., since 2011. He served as Achaogen’s Chief Executive Officer from 2011 until 2017, and as its Chief Medical Officer from 2011 to 2014. He has served on the board of directors of Zymeworks since February 2017. He served on the board of directors of Relypsa from 2014 until 2016, when it was acquired by Galenica AG.
Kenneth has an M.B. Ch.B. (Bachelor of Medicine and Surgery) degree from the Faculty of Medicine at the University of Glasgow, U.K. He is a Fellow of the Royal College of Surgeons (FRCS, Glasg), and a Fellow of the Royal College of Pathologists (FRCPath). Dr. Hillan has authored dozens of scientific publications and is a named inventor on almost 50 issued patents.

Covid-19 Broadcast
May 11, 2020
Live Event
May 10–12, 2021